ASCO 2023 | The role of targeted therapies in HER2+ and HR+ breast cancer

Yutaka Yamamoto, MD PhD, Kumamoto University Hospital, Kumamoto, Japan, comments on the current state of targeted therapies for HER2+ and HR+ breast cancer. Although clinically applicable results for immune checkpoint inhibitors have not yet been obtained for these types of breast cancer, antibody-drug conjugates such as trastuzumab deruxtecan (T-DXd) are being rapidly developed. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved